INKT
Price
$14.56
Change
-$0.03 (-0.21%)
Updated
Oct 9, 04:59 PM (EDT)
Capitalization
65.81M
PHVS
Price
$22.79
Change
-$0.19 (-0.83%)
Updated
Oct 9, 04:59 PM (EDT)
Capitalization
1.48B
27 days until earnings call
Interact to see
Advertisement

INKT vs PHVS

Header iconINKT vs PHVS Comparison
Open Charts INKT vs PHVSBanner chart's image
MiNK Therapeutics
Price$14.56
Change-$0.03 (-0.21%)
Volume$300
Capitalization65.81M
Pharvaris
Price$22.79
Change-$0.19 (-0.83%)
Volume$8.81K
Capitalization1.48B
INKT vs PHVS Comparison Chart in %
INKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INKT vs. PHVS commentary
Oct 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INKT is a Hold and PHVS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 10, 2025
Stock price -- (INKT: $14.55 vs. PHVS: $22.84)
Brand notoriety: INKT and PHVS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INKT: 54% vs. PHVS: 64%
Market capitalization -- INKT: $65.81M vs. PHVS: $1.48B
INKT [@Biotechnology] is valued at $65.81M. PHVS’s [@Biotechnology] market capitalization is $1.48B. The market cap for tickers in the [@Biotechnology] industry ranges from $107.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INKT’s FA Score shows that 0 FA rating(s) are green whilePHVS’s FA Score has 0 green FA rating(s).

  • INKT’s FA Score: 0 green, 5 red.
  • PHVS’s FA Score: 0 green, 5 red.
According to our system of comparison, both INKT and PHVS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INKT’s TA Score shows that 4 TA indicator(s) are bullish while PHVS’s TA Score has 5 bullish TA indicator(s).

  • INKT’s TA Score: 4 bullish, 3 bearish.
  • PHVS’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, PHVS is a better buy in the short-term than INKT.

Price Growth

INKT (@Biotechnology) experienced а -5.89% price change this week, while PHVS (@Biotechnology) price change was -1.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.88%. For the same industry, the average monthly price growth was +22.21%, and the average quarterly price growth was +89.30%.

Reported Earning Dates

PHVS is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+8.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PHVS($1.48B) has a higher market cap than INKT($65.8M). INKT YTD gains are higher at: 108.782 vs. PHVS (19.875). INKT has higher annual earnings (EBITDA): -9.92M vs. PHVS (-165.21M). PHVS has more cash in the bank: 200M vs. INKT (1.68M). PHVS has less debt than INKT: PHVS (634K) vs INKT (5.51M). INKT (0) and PHVS (0) have equivalent revenues.
INKTPHVSINKT / PHVS
Capitalization65.8M1.48B4%
EBITDA-9.92M-165.21M6%
Gain YTD108.78219.875547%
P/E RatioN/AN/A-
Revenue00-
Total Cash1.68M200M1%
Total Debt5.51M634K868%
TECHNICAL ANALYSIS
Technical Analysis
INKTPHVS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 8 days ago
81%
Bullish Trend 10 days ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 3 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
INKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCGEX21.940.08
+0.37%
NYLI PineStone Global Equity Class A
MDDCX28.22N/A
N/A
BlackRock Emerging Mkts Inv A
JAGRX64.43N/A
N/A
Janus Henderson VIT Research Instl
FFTMX22.54N/A
N/A
Fidelity Advisor Asset Manager 50% M
FMPFX40.18N/A
N/A
Nuveen Small Cap Growth Opp R6